Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of clevidipine butyrate emulsion for hypertensive emergencies and sub-acute emergencies
ChiCTR2200063062Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clevidipine in hypertensive emergency and hypertensive urgency (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Diastolic blood pressure. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
clevidipine
03
Conditions
hypertensive emergencyhypertensive urgency
Beyond the preview
Go deeper on ChiCTR2200063062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063062.